Patent ID: 11926642
Assignee: PFIZER INC.
Field: Organic fine chemistry (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 10:
11. A pharmaceutical composition comprising a therapeutically effective amount of (3S)-3-({N-[(4-methoxy-1H-indol-2-yl)carbonyl]-L-leucyl}amino)-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butyl dihydrogen phosphate, or a pharmaceutically acceptable salt, solvate or hydrate thereof, a pharmaceutically acceptable carrier and a buffering agent wherein:
a) the pharmaceutically acceptable salt is selected from the group consisting of benzathine, calcium, choline, diethylamine, diolamine, magnesium, meglumine, lysine, piperazine, potassium, tris(hydroxymethyl)aminomethane and sodium;
b) the molar ratio of the salt counterion to the (3S)-3-({N-[(4-methoxy-1H-indol-2-yl)carbonyl]-L-leucyl}amino)-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butyl dihydrogen phosphate in the pharmaceutically acceptable salt is approximately 0.5:1 to approximately 3:1; and
c) the buffering agent is selected from the group consisting of phosphoric acid, citric acid, maleic acid, tartaric acid, lactic acid and acetic acid.